What are the dosing guidelines for hydroxyurea (Hydrea) in adults with sickle cell disease, polycythemia vera, essential thrombocythemia, and in pediatric patients?

Hydroxyurea (Hydrea) Dosing Guidelines

For adults with polycythemia vera and essential thrombocythemia, start hydroxyurea at 500 mg twice daily (approximately 15-20 mg/kg/day), escalating to at least 2 g/day over 3 months to assess response; for children with sickle cell disease (HbSS or HbSβ⁰-thalassemia), initiate at 15-20 mg/kg/day and escalate to maximum tolerated dose of 25-35 mg/kg/day for optimal clinical benefit.

Myeloproliferative Neoplasms (Polycythemia Vera & Essential Thrombocythemia)

Starting Dose

• Initial dose: 500 mg twice daily (approximately 15-20 mg/kg/day) 1, 2
• Alternative starting approach: 15 mg/kg/day to minimize early cytopenia risk 2

Dose Escalation

• Target dose: At least 2 g/day (2.5 g/day if body weight >80 kg for ET) 1
• Assess response after 3 months at target dose before declaring resistance 3, 1, 3
• Maximum dose tested: 30 mg/kg/day (loading dose in older studies) 4

Treatment Goals

• Polycythemia Vera: Hematocrit <45% without phlebotomy, platelet count <400 × 10⁹/L, WBC <10 × 10⁹/L 1, 5
• Essential Thrombocythemia: Platelet count <400 × 10⁹/L (optimal target) 3

Monitoring

• CBC every 2 weeks during dose escalation 2
• Once stable: CBC every 4 weeks 2
• Adjust dose if ANC <1.0 × 10⁹/L, platelets <100 × 10⁹/L (PV) or <50 × 10⁹/L (PMF), or hemoglobin <10 g/dL 1, 3

Resistance/Intolerance Criteria

Hydroxyurea is considered ineffective if after 3 months at ≥2 g/day 1, 5:

• PV: Need for phlebotomy to maintain hematocrit <45%, OR uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L)
• ET: Platelet count >600 × 10⁹/L (>400 × 10⁹/L with body weight >80 kg requiring 2.5 g/day)
• Dose-limiting toxicity at any dose required for response

Important caveat: Use hydroxyurea with caution in patients <40 years old due to theoretical long-term leukemogenic concerns, though evidence is not definitive 1. Consider interferon-α as first-line in young patients requiring cytoreduction 6.

Sickle Cell Disease

Pediatric Dosing (Children with HbSS or HbSβ⁰-thalassemia)

Initiation:

• Start at 9 months of age, even without symptoms 7
• Initial dose: 15-20 mg/kg/day once daily 7

Dose Escalation Strategy:

• Escalate by 2.5-5 mg/kg every 8 weeks 8, 9
• Target: Maximum tolerated dose (MTD) of 25-35 mg/kg/day 8, 9
• MTD defined as mild myelosuppression without severe cytopenia 8

Evidence for dose escalation: A randomized trial comparing fixed-dose (19.2 mg/kg/day) versus escalated dosing (29.5 mg/kg/day) in sub-Saharan African children demonstrated superior clinical efficacy with dose escalation—43% reduction in sickle cell-related adverse events, 43% reduction in pain crises, 73% reduction in acute chest syndrome, and 79% reduction in hospitalizations, with equivalent safety 9. Extended follow-up over 8 years confirmed sustained benefits with mean dose of 28.2 mg/kg/day 8.

Adult Dosing

• Same principles apply: start 15-20 mg/kg/day, escalate to MTD 10
• Formulations: capsules, fast-dissolving tablets, or compounded liquid 7

Monitoring

• CBC and reticulocyte count every 1-3 months depending on treatment duration and dose stability 7
• Hold dose if ANC <2.0 × 10⁹/L, platelets <80 × 10⁹/L, hemoglobin <5 g/dL, or reticulocytes <80 × 10⁹/L if hemoglobin <9 g/dL 10

Dose Adjustments for Renal Impairment

Critical for all indications: Reduce dose by approximately 50% if creatinine clearance <60 mL/min or ESRD on hemodialysis, as hydroxyurea exposure increases by 64% in renal impairment 10.

Key Safety Considerations

Common Adverse Effects

• Myelosuppression (dose-limiting, usually transient) 2, 4
• Mucocutaneous changes: hyperpigmentation, nail changes, oral/leg ulcers 1, 10
• GI symptoms: nausea, diarrhea 2

Serious Toxicities

• Leg ulcers (indication to discontinue) 1, 3
• Pneumonitis, fever (rare but require discontinuation) 1
• Theoretical leukemogenic risk (not definitively proven in isolation) 2, 11

Handling Precautions

Caregivers must wear disposable gloves when handling capsules; do not open capsules; wash hands before and after contact 10. If capsule contents contact skin, wash immediately with soap and water; if eye contact occurs, flush for 15 minutes 10.

Pregnancy: Hydroxyurea is teratogenic; use interferon-α in women of childbearing age requiring cytoreduction 2.